PERSONALISED HEALTHCARE &
|Date:||3 May - 2011|
|Venue:||Courtyard by Marriott Stockholm|
Dr. Samantha Budd Vice President Translational Sciences CNS & Pain IMed
Professor Agneta Nordberg
MD PhD Professor, Director, Alzheimer Neurobiology Center
Dr. Magnus Sjögren Vice President Global Exploratory Development
UCB S. A.
Dr. Hugh Salter Principal Scientist
Dr. Holly D. Soares Director Clinical Biomarkers Neuroscience
BRISTOL-MYERS SQUIBB COMPANY (USA)
Dr. Caroline Graff Associate Professor, Department of Neurobiology, Care Sciences and Society
Dr. Oskar Hansson Associate Professor Clinical Memory Research Unit, Department of Clinical Sciences Malmö
Elisabetta Vaudano DVM PhD Principal Scientific Officer
INNOVATIVE MEDICINES INITIATIVE JOINT UNDERTAKING (IMI)
The Life Science industry moves in the direction towards predictive and preventive medicine, Personalised Healthcare. This is a paradigm shift from today's reactive medicine to proactive medicine in the future. By applying pharmacogenomics it is possible to give the right drug at the right time in order to customise drug therapies to individual patients genetic make up.
Neurodegenerative diseases are a heterogeneous condition with a need to deliver customised treatments to slow down or prevent further progression. By looking at CSF biomarkers it is possible to find out which patient groups that responds on different treatments. Today CSF Aβ1-42, total CSF tau protein and P-Tau18P represent three levels of biomarkers to enable physicians to identify early stage of the Alzheimer's disease and other neurodegenerative diseases' pathogenic progression. By combining genetic and molecular approaches to identify individual patient groups, scientists are able to develop a predictive, preventive, personalised and participatory healthcare programme to improve elderly people's well-being in the coming years.
This flagship event will examine the role of a P4 Medicine approach to fully capture the potential of CSF biomarkers to customise treatments to prevent or slow down the progression of neurodegenerative diseases. Our distinguished speaker panel will provide your CNS Drug Discovery organisation with a platform to successfully design personalised treatments to tackle neurodegenerative conditions such as Alzheimer's and Parkinson's disease, frontotemporal dementia and related Tauopathies.
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Vice Presidents, Directors and Heads within: